A variety of therapeutic options are available to patients with recurrent bladder cancer. Recent studies have suggested that the combination of Gemzar® and Platinol® represents the optimal current combination for treatment of advanced or metastatic bladder cancer. This patient received this combination but more than a yearago.
Less is known about how to deal with recurrent metastatic disease. NCCN says: "No standard therapy exists in this setting. Options include single agent therapy with a taxane or premetrexed...".In one trial, docetaxel and gemcitabine combination therapy in patients with progressing regional or metastatic transitional cell carcinoma who had failed a prior chemotherapy treatment. Five patients obtained an objective response for an overall response rate of 17% (90% confidence interval, 7-33%). One patient achieved a complete clinical response. The median overall survival of the group was 7.7 months.The authors concluded that for patients who have failed a previous chemotherapy regimen, this gemcitabine-docetaxel combination may be a useful alternative; however, it was obviously not a very active regimen.
NCCN.ORG, Bladder cancer Manola JB, Dreicer R, Wilding G. Gemcitabine and docetaxel in advanced carcinoma of the urothelium: report of a phase II Eastern Cooperative Oncology Group trial. Program and abstracts of the American Society of Clinical Oncology 38th Annual Meeting, May 18-21, 2002; Orlando, Florida. Abstract 796
Dreicer R, Manola J, Schneider DJ, Schwerkoske JF, George CS, Roth BJ, Wilding G; Eastern Cooperative Oncology Group. Phase II trial of gemcitabine and docetaxel in patients with advanced carcinoma of the urothelium: a trial of the Eastern Cooperative Oncology Group.Cancer. 2003 Jun 1;97(11):2743-7. Galsky, Matthew D. The Role of Taxanes in the Management of Bladder Cancer Oncologist 2005 10: 792-798
Galsky, Matthew D.
The Role of Taxanes in the Management of Bladder Cancer
Oncologist 2005 10: 792-798
Comments